ReviewCancers2019
Gene Therapy for Liver Cancers: Current Status from Basic to Clinics.
Review in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 43 citations in OpenAlex.
- Logic-Gated HSV-TK/GCV Suicide Gene Circuit for Triple-Negative Breast Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Developing Potent Therapeutics for Liver Cancer Chemoresistance via an RNA Nanotech and Series-Circuit-Christmas-Bulb Mechanism Targeting ABC Transporters.Molecular pharmaceutics · 2026Review
- Research on Anti-tumor Pharmacodynamics of Multi-functional Magnetic Lipid Polymer with Specific Targeted Transmission of siRNA and its Toxicity Evaluation.Current pharmaceutical design · 2026Article
- Glycogen for Smyd3-antisense oligonucleotide delivery and enhanced liver cancer gene therapy.RSC advances · 2025Article
- Metastatic hepatic carcinoma: Mechanisms, emerging therapeutics, and future perspectives.iScience · 2025Review
- A Review on the Extraction, Structural Analysis, and Antitumor Mechanisms ofFoods (Basel, Switzerland) · 2025Review
- Intelligent Hydrogel-Assisted Hepatocellular Carcinoma Therapy.Research (Washington, D.C.) · 2024Review
- Therapeutic options in hepatocellular carcinoma: a comprehensive review.Clinical and experimental medicine · 2023Review
- Review
- Hybrid Polydimethylsiloxane (PDMS) Incorporated Thermogelling System for Effective Liver Cancer Treatment.Pharmaceutics · 2022Article
- Establishment of a pancreatic cancer animal model using the pancreas-targeted hydrodynamic gene delivery method.Molecular therapy. Nucleic acids · 2022Article
- Zwitterionic Modification of Polyethyleneimine for EfficientInternational journal of molecular sciences · 2022Article
- The Current Status of SSRP1 in Cancer: Tribulation and Road Ahead.Journal of healthcare engineering · 2022Review
- Clinical Advances of siRNA-Based Nanotherapeutics for Cancer Treatment.Pharmaceutics · 2021Review
- Effect of Lenvatinib on a Hepatocellular Carcinoma with Fibroblast Growth Factor Receptor 4 Expression: A Case Report and Review of the Literature.Internal medicine (Tokyo, Japan) · 2021Review
- Therapeutic Approaches for Metastases from Colorectal Cancer and Pancreatic Ductal Carcinoma.Pharmaceutics · 2021Review
- Gene Therapy in Cancer Treatment: Why Go Nano?Pharmaceutics · 2020Review
- Article
- Strategies for Targeting Gene Therapy in Cancer Cells With Tumor-Specific Promoters.Frontiers in oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The liver is a key organ for metabolism, protein synthesis, detoxification, and endocrine function, and among liver diseases, including hepatitis, cirrhosis, malignant tumors, and congenital disease, liver cancer is one of the leading causes of cancer-related deaths worldwide. Conventional therapeutic options such as embolization and chemotherapy are not effective against advanced-stage liver cancer; therefore, continuous efforts focus on the development of novel therapeutic options, including molecular targeted agents and gene therapy. In this review, we will summarize the progress toward the development of gene therapies for liver cancer, with an emphasis on recent clinical trials and preclinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.